| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.
|
Science
|
2010
|
9.61
|
|
2
|
Early versus standard antiretroviral therapy for HIV-infected adults in Haiti.
|
N Engl J Med
|
2010
|
8.72
|
|
3
|
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.
|
AIDS
|
2004
|
4.64
|
|
4
|
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.
|
Clin Infect Dis
|
2005
|
3.47
|
|
5
|
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.
|
PLoS One
|
2009
|
3.40
|
|
6
|
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
|
Clin Infect Dis
|
2007
|
3.05
|
|
7
|
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
|
JAMA
|
2002
|
2.96
|
|
8
|
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.
|
J Infect Dis
|
2010
|
2.45
|
|
9
|
Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals.
|
Ann Intern Med
|
2005
|
2.26
|
|
10
|
Novel clinical trial designs for the development of new antiretroviral agents.
|
AIDS
|
2012
|
2.01
|
|
11
|
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.
|
J Infect Dis
|
2010
|
1.91
|
|
12
|
Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.
|
J Infect Dis
|
2008
|
1.91
|
|
13
|
Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.
|
J Infect Dis
|
2007
|
1.89
|
|
14
|
In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject.
|
J Virol
|
2008
|
1.84
|
|
15
|
Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.
|
Ann Intern Med
|
2014
|
1.75
|
|
16
|
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.
|
AIDS
|
2004
|
1.74
|
|
17
|
Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095.
|
J Acquir Immune Defic Syndr
|
2007
|
1.64
|
|
18
|
Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.
|
J Infect Dis
|
2009
|
1.61
|
|
19
|
Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095.
|
Clin Infect Dis
|
2010
|
1.53
|
|
20
|
Raltegravir: the first HIV type 1 integrase inhibitor.
|
Clin Infect Dis
|
2009
|
1.53
|
|
21
|
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.
|
Pharmacogenet Genomics
|
2012
|
1.52
|
|
22
|
When to start antiretroviral therapy?
|
Clin Infect Dis
|
2008
|
1.52
|
|
23
|
Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals.
|
Bull World Health Organ
|
2008
|
1.49
|
|
24
|
Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.
|
J Infect Dis
|
2004
|
1.37
|
|
25
|
Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359.
|
J Acquir Immune Defic Syndr
|
2005
|
1.33
|
|
26
|
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.
|
J Infect Dis
|
2004
|
1.30
|
|
27
|
The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects.
|
AIDS
|
2005
|
1.26
|
|
28
|
Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).
|
J Acquir Immune Defic Syndr
|
2007
|
1.20
|
|
29
|
Adherence to antiretroviral therapy: how much is enough?
|
Clin Infect Dis
|
2006
|
1.19
|
|
30
|
Invasive meningococcal disease in men who have sex with men.
|
Ann Intern Med
|
2013
|
1.19
|
|
31
|
Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection.
|
AIDS Res Hum Retroviruses
|
2008
|
1.15
|
|
32
|
Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity.
|
Clin Infect Dis
|
2011
|
1.14
|
|
33
|
Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.
|
J Acquir Immune Defic Syndr
|
2010
|
1.14
|
|
34
|
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.
|
Nature
|
2016
|
1.13
|
|
35
|
CCR5 antagonism in HIV infection: current concepts and future opportunities.
|
Annu Rev Med
|
2011
|
1.13
|
|
36
|
Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus.
|
J Infect Dis
|
2005
|
1.12
|
|
37
|
Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti.
|
J Int AIDS Soc
|
2012
|
1.11
|
|
38
|
Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects.
|
J Infect Dis
|
2004
|
1.10
|
|
39
|
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.
|
J Infect Dis
|
2002
|
1.07
|
|
40
|
Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.
|
J Acquir Immune Defic Syndr
|
2010
|
1.04
|
|
41
|
The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients.
|
HIV Clin Trials
|
2011
|
1.04
|
|
42
|
Design issues in initial HIV-treatment trials: focus on ACTG A5095.
|
Antivir Ther
|
2006
|
1.04
|
|
43
|
Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals.
|
AIDS Res Hum Retroviruses
|
2010
|
1.04
|
|
44
|
Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s).
|
HIV Clin Trials
|
2010
|
1.03
|
|
45
|
The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850).
|
J Infect Dis
|
2002
|
1.01
|
|
46
|
Proteinuria, creatinine clearance, and immune activation in antiretroviral-naive HIV-infected subjects.
|
J Infect Dis
|
2009
|
1.00
|
|
47
|
Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.
|
J Acquir Immune Defic Syndr
|
2011
|
0.97
|
|
48
|
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.
|
Clin Infect Dis
|
2009
|
0.96
|
|
49
|
Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.
|
J Infect Dis
|
2008
|
0.96
|
|
50
|
Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIV.
|
J Acquir Immune Defic Syndr
|
2010
|
0.94
|
|
51
|
HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
|
J Virol
|
2011
|
0.94
|
|
52
|
Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis.
|
Clin Infect Dis
|
2013
|
0.93
|
|
53
|
Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants.
|
Pac Symp Biocomput
|
2011
|
0.91
|
|
54
|
Case-control study of diabetes mellitus in HIV-infected patients.
|
J Acquir Immune Defic Syndr
|
2004
|
0.91
|
|
55
|
Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients.
|
HIV Clin Trials
|
2008
|
0.88
|
|
56
|
A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086.
|
J Infect Dis
|
2006
|
0.88
|
|
57
|
Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapy.
|
Antivir Ther
|
2002
|
0.87
|
|
58
|
Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions.
|
J Clin Microbiol
|
2009
|
0.85
|
|
59
|
Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases.
|
HIV Clin Trials
|
2011
|
0.84
|
|
60
|
Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development.
|
HIV Clin Trials
|
2012
|
0.84
|
|
61
|
Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095.
|
J Am Stat Assoc
|
2012
|
0.84
|
|
62
|
Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.
|
Pharmacogenet Genomics
|
2015
|
0.84
|
|
63
|
Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study).
|
Clin Infect Dis
|
2005
|
0.82
|
|
64
|
A comparison of three initial antiretroviral AIDS regimens.
|
N Engl J Med
|
2007
|
0.82
|
|
65
|
New antiretroviral agents for the treatment of HIV infection.
|
Curr HIV/AIDS Rep
|
2004
|
0.81
|
|
66
|
Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
|
AIDS
|
2015
|
0.81
|
|
67
|
Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.
|
J Virol
|
2012
|
0.79
|
|
68
|
Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.
|
Antimicrob Agents Chemother
|
2012
|
0.78
|
|
69
|
Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359.
|
HIV Clin Trials
|
2007
|
0.78
|
|
70
|
Brief report: efficacy and treatment-limiting toxicity with the concurrent use of lopinavir/ritonavir and a third protease inhibitor in treatment-experienced HIV-infected patients.
|
J Acquir Immune Defic Syndr
|
2003
|
0.78
|
|
71
|
Modeling clinical endpoints as a function of time of switch to second-line ART with incomplete data on switching times.
|
Biometrics
|
2013
|
0.77
|
|
72
|
Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS.
|
J Acquir Immune Defic Syndr
|
2014
|
0.76
|
|
73
|
Vicriviroc and peripheral neuropathy: results from AIDS Clinical Trials Group 5211.
|
HIV Clin Trials
|
2010
|
0.76
|
|
74
|
New antiretroviral agents.
|
Curr Infect Dis Rep
|
2007
|
0.76
|
|
75
|
Cost-Effectiveness of Meningococcal Vaccination Among Men Who Have Sex With Men in New York City.
|
J Acquir Immune Defic Syndr
|
2016
|
0.75
|
|
76
|
Antiretroviral therapy: when and what to start-- an American perspective.
|
Curr HIV/AIDS Rep
|
2004
|
0.75
|
|
77
|
Corrigendum: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.
|
Nature
|
2016
|
0.75
|
|
78
|
Switching antiretroviral therapy: why, when and how.
|
IAPAC Mon
|
2006
|
0.75
|